Itolizumab IV infusion + Best supportive care (BSC)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Respiratory Distress Syndrome
Conditions
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
Trial Timeline
May 1, 2020 → Jul 7, 2020
NCT ID
NCT04475588About Itolizumab IV infusion + Best supportive care (BSC)
Itolizumab IV infusion + Best supportive care (BSC) is a phase 2 stage product being developed by Biocon for Acute Respiratory Distress Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04475588. Target conditions include Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19.
What happened to similar drugs?
20 of 20 similar drugs in Acute Respiratory Distress Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04475588 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Respiratory Distress Syndrome